Discovery of a first-in-class PROTAC degrader of histone lysine demethylase KDM4
- 20 February 2025
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 288, 117410
Abstract
No abstract availableKeywords
Funding Information
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- Guangzhou Municipal Science and Technology Bureau
- Guangdong Provincial Natural Science Foundation
This publication has 32 references indexed in Scilit:
- Targeting KDM4 family epigenetically triggers antitumour immunity via enhancing tumour‐intrinsic innate sensing and immunogenicityClinical and Translational Medicine, 2024
- Discovery of a PROTAC degrader for METTL3-METTL14 complexCell Chemical Biology, 2024
- Discovery of PVD-06 as a Subtype-Selective and Efficient PTPN2 DegraderJournal of Medicinal Chemistry, 2023
- Recent Advances with KDM4 Inhibitors and Potential ApplicationsJournal of Medicinal Chemistry, 2022
- Unravelling KDM4 histone demethylase inhibitors for cancer therapyDrug Discovery Today, 2021
- Design, Synthesis, and Biological Evaluation of Lysine Demethylase 5 C DegradersChemMedChem, 2021
- Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer ModelsACS Medicinal Chemistry Letters, 2017
- Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one DerivativesJournal of Medicinal Chemistry, 2016
- 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase InhibitorsJournal of Medicinal Chemistry, 2016
- Docking and Linking of Fragments To Discover Jumonji Histone Demethylase InhibitorsJournal of Medicinal Chemistry, 2015